Javascript must be enabled to continue!
Abstract 847: PIAS3 induction of apoptosis is p53-independent and has STAT3-independent mediators.
View through CrossRef
Abstract
Protein inhibitor of activated STAT3 (PIAS3) is an endogenous inhibitor of STAT3 that negatively regulates STAT3 transcriptional activity and cell growth and demonstrates limited expression in the majority of human squamous cell carcinomas of the lung. In the present study we sought to determine if PIAS3 inhibits cell growth in non-small cell lung cancer (NSCLC) cell lines by induction of apoptosis and further determine the dependence of PIAS3 activity on p53 status by using both wild-type and p53-null cells. Our results demonstrate that over-expression of PIAS3 promotes caspase 3 activation and PARP cleavage. Furthermore, the expression of pro-survival family members BclXL and Bcl-2 is decreased. These effects were observed after both transient and regulated expression of exogenous PIAS3 and were independent of p53 status. PIAS3 inhibition of STAT3 luciferase activity was also p53 independent. Microarray experiments were performed to further investigate the STAT3-dependence of PIAS3-induced apoptosis by comparing its gene expression signature with that of STAT3 siRNA treated cells. IPA pathway analysis showed that a number of genes related to cell death were significantly increased by PIAS3. Furthermore, a subset of apoptotic genes, including CIDEC and DAPK2, were uniquely expressed only after PIAS3 expression and not after STAT3 siRNA. Thus, PIAS3 may represent a promising lung cancer therapeutic target because of its p53-independent efficacy as well as its potential to synergize with direct STAT3 inhibitors.
Citation Format: Snehal Dabir, Yu Liu, Gary Wildey, Afshin Dowlati. PIAS3 induction of apoptosis is p53-independent and has STAT3-independent mediators. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 847. doi:10.1158/1538-7445.AM2013-847
American Association for Cancer Research (AACR)
Title: Abstract 847: PIAS3 induction of apoptosis is p53-independent and has STAT3-independent mediators.
Description:
Abstract
Protein inhibitor of activated STAT3 (PIAS3) is an endogenous inhibitor of STAT3 that negatively regulates STAT3 transcriptional activity and cell growth and demonstrates limited expression in the majority of human squamous cell carcinomas of the lung.
In the present study we sought to determine if PIAS3 inhibits cell growth in non-small cell lung cancer (NSCLC) cell lines by induction of apoptosis and further determine the dependence of PIAS3 activity on p53 status by using both wild-type and p53-null cells.
Our results demonstrate that over-expression of PIAS3 promotes caspase 3 activation and PARP cleavage.
Furthermore, the expression of pro-survival family members BclXL and Bcl-2 is decreased.
These effects were observed after both transient and regulated expression of exogenous PIAS3 and were independent of p53 status.
PIAS3 inhibition of STAT3 luciferase activity was also p53 independent.
Microarray experiments were performed to further investigate the STAT3-dependence of PIAS3-induced apoptosis by comparing its gene expression signature with that of STAT3 siRNA treated cells.
IPA pathway analysis showed that a number of genes related to cell death were significantly increased by PIAS3.
Furthermore, a subset of apoptotic genes, including CIDEC and DAPK2, were uniquely expressed only after PIAS3 expression and not after STAT3 siRNA.
Thus, PIAS3 may represent a promising lung cancer therapeutic target because of its p53-independent efficacy as well as its potential to synergize with direct STAT3 inhibitors.
Citation Format: Snehal Dabir, Yu Liu, Gary Wildey, Afshin Dowlati.
PIAS3 induction of apoptosis is p53-independent and has STAT3-independent mediators.
[abstract].
In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC.
Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 847.
doi:10.
1158/1538-7445.
AM2013-847.
Related Results
Abstract 1404: Novel STAT3 inhibitors targeting the STAT3 dimerization
Abstract 1404: Novel STAT3 inhibitors targeting the STAT3 dimerization
Abstract
Background The STAT3 pathway may drive prostate cancer (PCa) progression to metastatic castration-resistant prostate cancer (mCRPC). STAT3 may serve as a go...
Abstract B182: Nuclear sequestration of ErbB4 receptor tyrosine kinase by PIAS3.
Abstract B182: Nuclear sequestration of ErbB4 receptor tyrosine kinase by PIAS3.
Abstract
Background: ErbB4 is a member of EGFR/ErbB family of receptor tyrosine kinases (RTK). ErbB4 is subjected to regulated intramembrane proteolysis (RIP), resul...
Abstract 1705: 3D growth modulates the competition between STAT3 and STAT5 in breast cancer
Abstract 1705: 3D growth modulates the competition between STAT3 and STAT5 in breast cancer
Abstract
Approximately 13% of women are diagnosed with invasive breast cancer. Signal Transducer and Activator of Transcription 3 (STAT3) is a transcription factor t...
High P53 Protein Expression Level Independent of Mutational Status Is An Adverse Prognostic Factor for Survival in Acute Myeloid Leukemia
High P53 Protein Expression Level Independent of Mutational Status Is An Adverse Prognostic Factor for Survival in Acute Myeloid Leukemia
Abstract
Abstract 1490
Background:
The tumor suppressor p53 is frequently mutated in human cancer, including acut...
Abstract 599: Id4 acts as a tumor suppressor by inducing apoptosis and senescence in p53-dependent manner
Abstract 599: Id4 acts as a tumor suppressor by inducing apoptosis and senescence in p53-dependent manner
Abstract
The physiological mechanisms that can restore biological activity of mutant p53 is an area of high interest given that mutant p53 expression is observed in ...
Abstract 1706: Investigating the interaction between ETS family members and mutant p53
Abstract 1706: Investigating the interaction between ETS family members and mutant p53
Abstract
Cancer cases are on the rise globally requiring a deeper understanding of the disease and identification of novel therapeutic targets. Mutations in genes of...
Abstract 3500: Mitochondrially targeted p53 domains as a stand alone or adjunct to paclitaxel for the treatment of ovarian cancer
Abstract 3500: Mitochondrially targeted p53 domains as a stand alone or adjunct to paclitaxel for the treatment of ovarian cancer
Abstract
Although the main function of p53 is a nuclear transcription factor that has important roles in cell cycle arrest, DNA repair, and apoptosis, p53 can direct...
Panobinostat Inhibits JAK2/STAT3 Pathway in Multiple Myeloma.
Panobinostat Inhibits JAK2/STAT3 Pathway in Multiple Myeloma.
Abstract
Abstract 2849
Poster Board II-825
Histone deacetylase inhibitors (HDACi) are emerging as a potential therapy for Multiple Myel...

